galantamine used treatment cognitive decline mild moderate alzheimers disease various memory alkaloid extracted bulbs flowers galanthus nivalis common snowdrop galanthus caucasicus caucasian snowdrop galanthus woronowii voronovs snowdrop members family amaryllidaceae narcissus daffodil leucojum aestivum snowflake lycoris including lycoris radiata red spider also produced synthetically galantamine isolated first time bulbs galanthus nivalis common snowdrop bulgarian chemist dimitar paskov team active ingredient extracted identified studied particular relation acetylcholinesterase acheinhibiting first industrial process developed however fullscale synthesis upscaled homers odyssey god hermes gives odysseus herb black root milklike flower called moly hermes claims make odysseus immune sorceress circes drugs believed moly snowdrop galanthus nivalis source descriptions moly given greek physician herbalist dioscorides support molys identity galanthus proposed drugs circe used extract datura stramonium also known jimsonweed causes memory loss would give basis snowdrops use antidote datura stramonium anticholinergic galantamine acetylcholinesterase galantamine indicated treatment mild moderate vascular dementia united states approved food drug administration safe effective treatment mild moderate cholinesterase inhibitors galantamine may effective treating mild cognitive fda considers galantamine dual status prescription drug otc dietary alzheimers disease characterized impairment cholinergic one hypothesis impairment contributes cognitive deficits caused disease hypothesis forms basis use galantamine cholinergic enhancer treatment galantamine inhibits acetylcholinesterase enzyme hydrolyzes result acetylcholinesterase inhibition galantamine increases availability acetylcholine synaptic additionally galantamine binds allosteric sites nicotinic receptors causes conformational allosteric modulation increases nicotinic receptors response activation presynaptic nicotinic receptors increases release acetylcholine increasing availability galantamines competitive inhibition acetylcholinesterase allosteric nicotinic modulation serves dual mechanism reduce prevalence negative side effects associated galantamine nausea vomiting doseescalation scheme may use doseescalation scheme well accepted countries galantamine doseescalation scheme alzheimers treatment involves recommended starting dosage mg galantamine tablets given twice day minimum weeks dosage may increased mg given twice day minimum weeks mgday treatment may increased mg given twice day dosage increases based upon assessment clinical benefit well tolerability previous treatment interrupted three days process usually restarted beginning starting dosage reescalating current found dosage mgday optimal product supplied prescription form twiceaday tablets onceaday extendedrelease capsules oral galantamines side effect profile similar cholinesterase inhibitors gastrointestinal symptoms notable commonly observed one study reports higher proportions patients treated galantamine experiencing nausea vomiting opposed placebo another study using doseescalation treatment found incidences nausea would decrease baseline levels soon increase administered practice cholinesterase inhibitors might better tolerated however careful gradual titration three months may lead equivalent longterm us food drug administration fda international health authorities published alert galantamine based data two studies treatment mild cognitive impairment mci higher mortality rates seen drugtreated however reduced mortality alzheimers april fda approved labeling changes concerning form galantamine preparations liquid regular tablets extended release tablets warning risk bradycardia slow resting heart rate sometimes atrioventricular block especially predisposed persons time risk syncope fainting seems increased relative placebo randomized controlled trials bradycardia reported frequently galantaminetreated patients placebotreated patients rarely severe rarely led treatment side effects reported alzheimers disease related galantamines chemical structure contains tertiary amine neutral ph tertiary amine often bond hydrogen appear mostly ammonium galantamine potent allosteric potentiating ligand human nicotinic acetylcholine receptors nachrs chickenmouse nachrs certain areas binding allosteric site nachrs conformational change occurs increases receptors response modulation nicotinic cholinergic receptors cholinergic neurons turn causes increase amount acetylcholine however recent studies suggest galantamine functionally act human nachrs positive allosteric galantamine also works weak competitive reversible cholinesterase inhibitor areas inhibiting acetylcholinesterase increases concentration thereby action acetylcholine certain parts brain galantamines effects nachrs complementary acetylcholinesterase inhibition make dual mechanism action hypothesized action might relieve symptoms alzheimers galantamine pure form white powder atomic resolution structure complex galantamine target acetylcholinesterase determined xray crystallography pdb code see evidence galantamine alters course underlying dementing absorption galantamine rapid complete shows linear pharmacokinetics well absorbed absolute oral bioavailability terminal elimination halflife seven hours peak effect inhibiting acetylcholinesterase achieved one hour single oral dose mg healthy volunteers coadministration food delays rate galantamine absorption affect extent plasma protein binding galantamine relatively low approximately dose galantamine metabolised liver vitro studies shown hepatic involved galantamine metabolism within hours intravenous oral administration approximately dose galantamine excreted unreacted humans several metabolic pathways galantamine pathways lead formation number different one metabolites may result formed glucuronidation additionally galantamine may undergo oxidation demethylation nitrogen atom forming two possible galantamine undergo demethylation oxygen atom forming intermediate undergo glucuronidation sulfate lastly galantamine may oxidized reduced finally undergoing demethylation oxidation nitrogen atom demethylation subsequent glucuronidation oxygen razadyne er onceaday formulation poor metabolizers drug exposures approximately higher extensive metabolizers population genetic mutation however drug individually titrated tolerability specific dosage adjustment necessary population since galantamine metabolized inhibiting either isoenzymes increase cholinergic effects inhibiting enzymes may lead adverse found paroxetine inhibitor increased bioavailability galantamine inhibitors ketoconazole erythromycin increased bioavailability galantamine since alkaloid isolated botanical sources containing low amounts weight extraction yields although galantamine produced natural resources also many industrial syntheses janssen orthomcneil pharmaceutical shire takeda pharmaceutical toxicity organophosphates results primarily action irreversible inhibitors inhibiting acetylcholinesterase causes increase acetylcholine enzyme longer available catalyze peripheral nervous system acetylcholine accumulation cause overstimulation muscarinic receptors followed desensitization nicotinic leads severe skeletal muscle fasciculations involuntary effects central nervous system include anxiety restlessness confusion ataxia tremors seizures cardiorespiratory paralysis reversible acetylcholinesterase inhibitor galantamine potential serve effective organophosphate poisoning treatment preventing irreversible acetylcholinesterase additionally galantamine anticonvulsant properties may make even desirable research supported part us army led us patent application use galantamine andor derivatives treatment organophosphate indications use galantamine patent application include poisoning nerve agents including limited soman sarin vx tabun novichok agents galantamine studied research cited patent application use along wellrecognized nerve agent antidote atropine according investigators unexpected synergistic interaction occurred galantamine atropine amount mgkg higher increasing dose galantamine mgkg decreased dose atropine needed protect experimental animals toxicity soman dosages times dose generally required kill half experimental galantamine given addition risperidone autistic children shown improve symptoms autism irritability lethargy social additionally cholinergic nicotinic receptors believed play role attentional studies noted cholinergic nicotinic treatments improved attention autistic hypothesized galantamines dual action mechanism might similar effect treating autistic children galantamine may limited use reducing sideeffects anesthetics ketamine diazepam one study control group patients given ketamine diazepam underwent anesthesia experimental group given ketamine diazepam nivalin active ingredient degree drowsiness disorientation two groups assessed minutes group taken nivalin found alert minutes though approved fda interest recreational use galantamine purported ability induce lucid dreaming one study provided limited evidence practice although notable authors financial ties lucidity httpsenwikipediaorgwikigalantamine